In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Risk Minimisation Activities: clarifications on Circular No. 635

Risk Minimisation Activities: clarifications on Circular No. 635

by In2Pharma | Feb 26, 2021 | News

Belgium Circular No. 635 (4 May 2018) details the approval procedure for risk minimisation activities (RMA). Certain paragraphs of this circular could be misinterpreted and specific situations were not considered. Therefore, the FAMHP provided more...

Recent Posts

  • Introduction to FAMHP portal – manufacturing inspections
  • RD export 19/01/2023 – mandatory application for export
  • Fiscal importation of medicines from 3rd countries
  • NARCOTIC/PSYCHOTROPIC LEGISLATION: important clarifications concerning the narcotic order forms
  • Negative formulations no longer allowed on packaging of medicinal products for human use

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België